Quantum BioPharma announces expiration of warrants held by hedge funds

Quantum announces the expiration at 5pm EST of 53,147 warrants. All warrants were issued to hedge funds and investment funds as part of a previous financing completed on October 20, 2020. This represents the very last tranche of warrants issued to hedge funds and investment funds. Quantum BioPharma also re-iterates October 27, 2025 as the record date for the distribution of contingent value rights to holders of its Class B Subordinate Voting Shares on a one-for-one basis, advancing the Company’s previously disclosed plan in the Company’s press releases dated June 13, 2025, and October 3, 2025 to deliver a litigation-linked CVR to shareholders of record as of the record date. Each CVR will entitle the holder to receive a pro rata portion of a minimum of 10% and up to 50% of the net proceeds ultimately recovered by the Company in connection with its legal action against CIBC World Markets, RBC Dominion Securities, and others, which alleges stock price manipulation and spoofing and seeks damages in excess of $700M. No payment will occur under the CVRs unless and until the Company receives net proceeds from the Litigation following a settlement or a final, non-appealable judgment. There is no guarantee that any net proceeds will be received or that any payment will be made under the CVRs, as a result of the Litigation.